Captopril Denk

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Captopril Denk

What is Captopril Denk?

Captopril Denk is a pharmaceutical preparation containing the active substance captopril. It belongs to a category of medications known as angiotensin-converting enzyme inhibitors, commonly referred to as ACE inhibitors.

Mechanism of Action

The medication works by interfering with the body's production of angiotensin II, a naturally occurring substance that causes blood vessels to tighten and narrow. By inhibiting the enzyme responsible for this process, the medication helps blood vessels to relax and widen. This action facilitates easier blood flow throughout the circulatory system and reduces the pressure against which the heart must pump.

Therapeutic Areas

Captopril Denk is primarily utilized in the management of cardiovascular conditions where the regulation of blood pressure or heart function is required. This includes:

  • Hypertension: It is used to lower high blood pressure levels.
  • Heart Failure: It can be used to assist the heart in pumping blood more efficiently, often as part of a broader management plan.
  • Post-Myocardial Infarction: In certain cases following a heart attack, it is used to improve long-term survival and support heart muscle function.
  • Diabetic Nephropathy: It may be used to manage kidney issues in patients with type 1 diabetes by slowing the progression of kidney damage.

What side effects are possible with Captopril Denk?

Possible side effects and safety information

The safety profile of Captopril Denk, an Angiotensin-Converting Enzyme (ACE) inhibitor, is formally documented by regulatory authorities, classifying possible adverse reactions by frequency and affected physiological systems. This information is derived from official sources such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).


Adverse Reaction Scope

Adverse reactions are organized into System-Organ Classes (SOCs) and categorized by frequency:

  • Common Reactions (1/100): This tier includes reactions such as dizziness, taste impairment (dysgeusia), and the characteristic dry, irritating cough. Other common reports involve certain gastrointestinal issues (nausea, vomiting, diarrhoea) and skin reactions (rash, pruritus).
  • Uncommon and Rare Reactions: These categories document less frequent events, including hypotension, tachyarrhythmia, sleep disorders, and headache.
  • Very Rare Reactions (< 1/10,000): This frequency documents severe potential reactions such as neutropenia/agranulocytosis (severe reduction in white blood cells), severe renal function disorders (including failure), and hepatotoxicity (impaired liver function).

Serious Adverse Reactions and Safety Constraints

Official labeling highlights specific clinically significant adverse reactions. These include Angioedema (swelling of the face, lips, or airway), which is a serious, potentially life-threatening event. The label also documents Severe Hypotension and electrolyte imbalances such as Hyperkalaemia (elevated serum potassium).

  • Time-Related Patterns: The risk of severe hypotension is noted as being highest early in the course of treatment, particularly in patients who are volume-depleted.
  • Population Constraints: The FDA includes a Black Box Warning against the use of Captopril during the second and third trimesters of pregnancy due to the risk of fetal morbidity and death. Increased risk of Neutropenia is noted for patients with impaired renal function or certain collagen vascular diseases. The medicine is contraindicated in patients with a history of swelling related to previous ACE inhibitor use.

This structured safety information provides a regulatory framework for understanding the potential outcomes associated with the medicine's use.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Captopril as primarily resulting in an exaggerated extension of its therapeutic effects.

Overdose Manifestations
Severe hypotension (excessively low blood pressure) and shock are the most prominently documented effects.
Other documented clinical signs include stupor or lethargy, bradycardia (slow heart rate), and vomiting.
Severe outcomes may escalate to acute renal failure and significant electrolyte disturbances.

Immediate medical care is required whenever overdose is suspected or if severe symptoms develop. Government guidance mandates that individuals seek immediate medical attention or contact a poison control center right away. Emergency services must be called immediately if the person has collapsed, has trouble breathing, or cannot be awakened.

Regulator-described procedural steps for managing overdose include placing the patient in the supine position and administering intravenous volume supplementation to counteract severe hypotension. For recent ingestion, gastric lavage or activated charcoal may be considered to prevent further absorption. Hemodialysis is officially documented as a means to effectively eliminate Captopril from the body. Patients with impaired renal function are noted in official labeling to be at increased risk of drug accumulation and subsequent severe effects.

Therapeutic Uses of Captopril Denk

Main Uses and Benefits of Captopril

Captopril belongs to the class of medications known as angiotensin-converting enzyme (ACE) inhibitors. It is used to manage conditions marked by increased physiological stress and symptoms related to systemic imbalance.

The main therapeutic areas for this medication involve managing hypertension (high blood pressure) and heart failure. Captopril assists with managing symptoms that create noticeable physiological strain, which contributes to easing the overall symptom load.


Main Clinical Applications

Captopril is applied in addressing major clinical scenarios, including hypertension, chronic heart failure, left ventricular dysfunction after a myocardial infarction (heart attack), and diabetic nephropathy (a kidney condition).

In these situations, the medication is used to support the body during difficult episodes by easing distress. It helps maintain stability when symptoms are more noticeable.

"This treatment supports patients during episodes of heightened discomfort and assists with maintaining functional stability."

Captopril also plays a role in managing conditions where functional stability becomes affected, particularly concerning symptoms linked to organ-specific functional stress. This provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for symptoms related to physical discomfort.

Eligibility and Restrictions for Use

Captopril Denk is only for use by Adults with established indications such as hypertension, heart failure, post-MI left ventricular dysfunction, and diabetic nephropathy. Eligibility is strictly defined by regulatory bodies and involves several population restrictions.

Populations Who Must Not Use (Contraindicated)

Classification Population/Condition
Absolute Prohibition History of Angioedema (swelling) related to any ACE inhibitor.
Hypersensitivity to captopril or any other ACE inhibitor.
Pregnancy during the second or third trimester.
Concomitant use with aliskiren in patients with diabetes mellitus or impaired renal function (GFR < 60).

Eligibility Restrictions and Special Use Populations

Classification Population/Condition
Conditional Use Patients with Impaired Renal Function require close monitoring and may need a lower initial dose.
Not Recommended Lactating mothers of new-borns or preterm infants; first trimester of pregnancy.
Use Not Established Children and adolescents, where safety and efficacy are not fully established; use requires careful medical supervision.
Required Caution Older adults and patients with conditions like collagen vascular disease often require a lower starting dose due to potential reduced organ function.

What should I know about interactions with other medicines?

Captopril Denk’s interaction profile is officially defined by specific pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Documented Interaction Restrictions

Co-administration with Sacubitril/Valsartan is contraindicated due to the significantly increased risk of angioedema, requiring a mandatory 36-hour separation period when switching administration. The use of Aliskiren is also contraindicated in patients with diabetes mellitus. Certain strong enzyme inhibitors, such as Mavorixafor and Abiraterone, are prohibited because they are documented to increase Captopril exposure through CYP2D6 inhibition.

Clinically Significant Interactions

Combinations with agents that increase serum potassium, such as Potassium-Sparing Diuretics and Potassium Supplements, carry a documented risk of hyperkalemia. This interaction is noted to be heightened in populations with renal insufficiency. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in a loss of the antihypertensive effect and an increased risk of renal impairment. Other antihypertensive medicines and alcohol are documented to contribute to an additive hypotensive effect. Furthermore, Lithium clearance is reduced when co-administered, resulting in elevated serum concentrations and a risk of toxicity. The product's absorption is documented to be decreased by food and Antacids, establishing an administration-timing rule that requires Captopril to be taken one hour before a meal.

Mechanism of Action

How Captopril Denk Works

Captopril Denk works by targeting and inhibiting the Angiotensin-Converting Enzyme (ACE), which is a key regulatory component of the body's system for controlling blood pressure and fluid balance. Its core action involves two intertwined systems: the Renin-Angiotensin-Aldosterone System (RAAS) and the Kinin-Kallikrein System (KKS).


Blocking Angiotensin II Formation and Vasoconstriction

Captopril is a competitive inhibitor that binds to ACE, preventing it from converting Angiotensin I into the vasoconstrictor, Angiotensin II. This molecular block leads to a reduction in circulating Angiotensin II levels. The resulting physiological consequence is the relaxation and widening of blood vessels (vasodilation), which lowers total peripheral resistance (afterload).


Modulating Fluid and Electrolyte Balance

By suppressing Angiotensin II, Captopril reduces the release of the hormone aldosterone from the adrenal glands. Lower aldosterone activity prompts the kidneys to increase the excretion of sodium and water while retaining potassium. This fluid-modulating mechanism results in a reduced total blood volume (preload) and contributes to a change in cardiac hemodynamic factors.


Modulating the Kinin-Kallikrein System

Captopril also inhibits the breakdown of the vasodilatory peptide bradykinin by ACE. Increased bradykinin levels augment the blood vessel widening initiated by the RAAS block, contributing to the change in systemic blood pressure. This simultaneous action modulates both the vasoconstrictor and the vasodilator systems.

Dosage and Administration Information

How to use Captopril Denk: Official Administration Guidelines

Captopril Denk is intended for oral administration as a tablet. The medicine's use is defined by regulatory posology that establishes a specific administration schedule relative to food. To maximize absorption, Captopril must be taken on an empty stomach, generally one hour before a meal.


The official regimen begins with a low starting dose (e.g., 6.25 mg to 25 mg) which is part of a divided daily use pattern, typically two or three times daily. The dose is then gradually increased (titrated) over a period of one to two weeks until the designated maintenance range is achieved. Maintenance doses commonly fall between 75 mg and 150 mg daily, administered in divided amounts.


Special Procedural Conditions

Special procedural conditions apply to the use of Captopril in certain patient populations. For instance, treatment initiation for high-risk conditions, such as post-myocardial infarction, is recommended to occur under close medical supervision. Furthermore, the initial dose and the dosing interval must be formally reduced and/or extended for patients with confirmed renal impairment (creatinine clearance leq 40 mL/min), a requirement that defines the population-specific use protocol. This medication is generally intended for long-term use in chronic indications.

Recent Clinical Evidence

Captopril Denk: Recent Clinical Evidence

Captopril is an angiotensin-converting enzyme (ACE) inhibitor with a well-established history in the management of cardiovascular conditions. Clinical research continues to evaluate its role across its primary indications, including hypertension and heart failure.


Efficacy and Cardiovascular Outcomes

Studies in patients with hypertension (high blood pressure) have demonstrated that Captopril is associated with significant reductions in both systolic and diastolic blood pressure. It is recognized in clinical guidelines as a first-line treatment option, used alone or in combination with other antihypertensive agents.

For patients who have experienced a myocardial infarction (heart attack), trials indicate that the administration of Captopril in clinically stable individuals with left ventricular dysfunction may be associated with improved long-term survival and reduced incidence of subsequent hospitalizations for heart failure.

Captopril's role in heart failure with reduced ejection fraction has also been extensively studied. Research suggests that its use, as part of goal-directed medical therapy, is correlated with a reduction in the risk of rehospitalization and improvement in overall survival rates.


Renal Protection and Tolerability

Evidence supports the use of Captopril in patients with diabetic nephropathy (a type of kidney disease common in people with diabetes). Clinical trials have demonstrated that Captopril may slow the progression of kidney damage in this population, typically evidenced by a reduction in proteinuria (protein in the urine).

In terms of tolerability, common adverse events reported across clinical practice and trials include a dry cough, dizziness, and changes in taste. Serious but rare adverse events, such as angioedema (swelling of the face, lips, tongue, or throat), have been documented, highlighting the need for careful patient monitoring.

Key Studies & References

  1. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial (SAVE Investigators)
  2. Captopril - StatPearls (for general indications, GDMT, and adverse events)
  3. Adverse Effects of Angiotensin-Converting Enzyme Inhibitors in Humans: A Systematic Review and Meta-Analysis of 378 Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Captopril Denk (FAQ)

Q: Why do some people on forums say they get a dry cough with Captopril Denk?

Official documents state that a dry, persistent, and nonproductive cough is a common side effect associated with the use of ACE inhibitors, including Captopril. This reaction is related to the drug's mechanism of action. The cough is generally noted to resolve after the medication is discontinued.


Q: Can Captopril Denk be taken with common over-the-counter pain relievers?

The use of Captopril with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include some common over-the-counter pain relievers, is noted to carry a documented risk. Official product information indicates that this combination may reduce the blood pressure-lowering effect of Captopril. Furthermore, combining these medicines can increase the risk of kidney problems and high potassium levels.


Q: Are there any specific foods or drinks to avoid while using Captopril Denk?

Regulatory documents state that using potassium supplements or salt substitutes that contain potassium can heighten a documented risk. Captopril can cause an increase in the blood's potassium levels (hyperkalemia), and adding further potassium sources can increase this risk.


Q: What are the signs that Captopril Denk might be causing a serious reaction?

Official safety information highlights several potential serious reactions. These include angioedema (swelling of the face, tongue, or throat) and signs of high potassium levels, such as an irregular heartbeat or muscle weakness. Safety documents also mention signs related to liver or kidney problems as documented in regulatory warnings.


Q: Is it true that Captopril Denk may interact with salt substitutes that contain potassium?

Yes, the official drug label confirms an interaction. Captopril can naturally increase serum potassium levels. Therefore, using salt substitutes or other products containing potassium is documented as being associated with a risk of hyperkalemia (excessively high potassium levels) in the blood.


Q: Can Captopril Denk cause swelling in the hands or feet?

Swelling in the hands, feet, or ankles may be a potential sign of a kidney problem, which is a possible adverse reaction documented in official sources. Swelling of the extremities can also occur with the severe reaction known as angioedema.


Q: Is Captopril Denk a drug that is studied for use in children?

According to official prescribing information, the safety and effectiveness of Captopril have not been fully established in pediatric patients. If the medicine is prescribed for children, the label emphasizes the need for careful medical supervision due to limited evidence in this population.


Q: How long does the blood pressure-lowering effect of Captopril Denk last?

The antihypertensive (blood pressure-lowering) effect is generally seen after the first dose. Regulatory information indicates that the overall blood pressure control appears to persist for the duration of the therapy.


Q: Does Captopril Denk's effectiveness change over time?

Studies and regulatory data examining the drug's use in chronic conditions, such as heart failure, indicate that the beneficial hemodynamic and clinical effects appear to persist for the duration of therapy. This suggests a consistent long-term effect when the medicine is used as prescribed.


Q: What is angioedema, and why is it mentioned as a possible side effect of Captopril Denk?

Angioedema is a sudden, severe swelling that typically affects the face, lips, tongue, or throat. It is highlighted in official warnings because it is a rare but potentially life-threatening adverse effect associated with all ACE inhibitors, including Captopril.


Q: Are there common signs that Captopril Denk might be making my blood pressure too low?

Symptoms that may suggest blood pressure is too low, known as hypotension, include feeling dizzy or lightheaded. Official safety documents recognize these effects, particularly when a person stands up quickly.


Q: Can Captopril Denk be taken with certain antacids?

Regulatory documents indicate that antacids can reduce the absorption of Captopril, which may lower its effectiveness in the body. The regulatory administration rule emphasizes that Captopril should be taken on an empty stomach, separate from antacid use, due to the risk of reduced absorption.


Q: Is Captopril Denk a diuretic (water pill)?

No, Captopril is classified as an Angiotensin I-Converting Enzyme (ACE) inhibitor. It works by blocking a key enzyme involved in narrowing blood vessels. While the drug affects the body's fluid and sodium balance, its primary action is not that of a diuretic.


Q: How long does it typically take for Captopril Denk to start lowering blood pressure?

The initial hemodynamic effects on blood pressure occur after the first dose. Regulatory documents indicate that the process to reach the desired long-term blood pressure control involves a gradual titration over a period of time.


Q: Does Captopril Denk contain penicillin or any sulfa ingredients?

According to the chemical description in official product information, Captopril is a synthetic compound containing a sulfhydryl group. It is not chemically classified as a penicillin or a sulfa drug.


Q: What happens if I miss a dose of Captopril Denk, generally speaking?

General patient information found in regulatory sources provides instruction for a missed dose. If a dose is missed, the recommendation is typically to take it as soon as remembered, unless it is nearly time for the next scheduled dose. It is specified that a double dose should not be taken.


Q: Can Captopril Denk affect lab test results?

Yes, regulatory labeling documents indicate that Captopril can affect certain lab test results. The potential for increased blood potassium levels (hyperkalemia) is documented, which is why official information mentions that the drug's use is associated with monitoring of kidney function and potassium levels.


Q: Is there a generic version of Captopril Denk available?

Official drug records and patient resources confirm that the active ingredient, captopril, is available as a generic medication.


Q: Does Captopril Denk interact with herbal supplements like St. John's Wort?

Herbal products like St. John's Wort are known in a general sense to potentially interfere with the effectiveness of many prescription medicines. The potential for these products to interfere with the effectiveness of Captopril is noted, as regulatory warnings apply to compounds that may affect drug metabolism.


Q: Is feeling more tired than usual a recognized side effect of Captopril Denk?

Yes, official safety information lists excessive tiredness, unusual weakness, or fatigue as a recognized side effect that patients may experience.


Q: Can Captopril Denk be taken with aspirin?

Official information indicates Captopril is sometimes used in combination with aspirin for specific conditions (e.g., after a heart attack), but drug interaction data suggests aspirin may decrease the overall therapeutic efficacy of Captopril.


Q: Why is it important to check blood pressure regularly when taking Captopril Denk?

Regulatory guidelines mention that regular blood pressure checks are generally necessary. This monitoring helps verify the treatment's effectiveness and helps avoid an excessive reduction in blood pressure.


Q: What are the general rules for stopping Captopril Denk if instructed by a healthcare provider?

Patient information from official sources emphasizes that the medication is intended for use as prescribed. Discontinuation of the drug is advised to occur only under medical supervision.


Q: Can Captopril Denk interact with diabetes medications?

Yes, the official drug label confirms Captopril may increase the blood pressure-lowering effect of certain diabetes medications. The label also mentions that Captopril is very rarely associated with low blood sugar (hypoglycemia).


Q: Do official documents mention Captopril Denk being associated with vision changes?

Official drug safety databases list a few vision-related events as rare side effects. These include disturbed vision, dry eye, and itchy eye, with blurred vision being noted as a very rare potential effect.


Q: Can Captopril Denk cause low blood sugar in people who do not have diabetes?

According to official adverse reaction data, low blood sugar, or hypoglycemia, is listed as a very rare potential side effect of Captopril.

How should Captopril Denk be stored and disposed of?

How to Store and Dispose of Captopril Denk?

The storage and disposal of Captopril tablets are subject to specific regulatory requirements to ensure product quality and safety.

Storage and Disposal Rule Regulatory Requirement
Required Storage Temperature Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F) (FDA Labeling).
Prohibited Environments Must be protected from excess heat, light, and moisture; do not freeze (NIH/MedlinePlus). Should not be stored in humid areas like the bathroom.
Container Requirements Keep the medication in the original container it came in, and ensure the container is tightly closed (NIH/MedlinePlus).
Child Safety Must be kept out of the sight and reach of children to prevent accidental ingestion (NIH/MedlinePlus).
Official Disposal Rules Dispose of unused or expired medicine according to local regulatory requirements (FDA Guidance). Captopril is not on the FDA's flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Captopril Denk found in:

A-Z Index: